Original Article
Live Attenuated versus Inactivated Influenza Vaccine in Infants and Young Children
N Engl J Med 2007; 356:685-696February 15, 2007
- Abstract
Background
Universal vaccination of children 6 to 59 months of age with trivalent inactivated influenza vaccine has recently been recommended by U.S. advisory bodies. To evaluate alternative vaccine approaches, we compared the safety and efficacy of intranasally administered live attenuated influenza vaccine with those of inactivated vaccine in infants and young children.
Methods
Children 6 to 59 months of age, without a recent episode of wheezing illness or severe asthma, were randomly assigned in a 1:1 ratio to receive either cold-adapted trivalent live attenuated influenza vaccine (a refrigeration-stable formulation of live attenuated intranasally administered influenza vaccine) or trivalent inactivated vaccine in a double-blind manner. Influenza-like illness was monitored with cultures throughout the 2004–2005 influenza season.
Results
Safety data were available for 8352 children, and 7852 children completed the study according to the protocol. There were 54.9% fewer cases of cultured-confirmed influenza in the group that received live attenuated vaccine than in the group that received inactivated vaccine (153 vs. 338 cases, P<0.001). The superior efficacy of live attenuated vaccine, as compared with inactivated vaccine, was observed for both antigenically well-matched and drifted viruses. Among previously unvaccinated children, wheezing within 42 days after the administration of dose 1 was more common with live attenuated vaccine than with inactivated vaccine, primarily among children 6 to 11 months of age; in this age group, 12 more episodes of wheezing were noted within 42 days after receipt of dose 1 among recipients of live attenuated vaccine (3.8%) than among recipients of inactivated vaccine (2.1%, P=0.076). Rates of hospitalization for any cause during the 180 days after vaccination were higher among the recipients of live attenuated vaccine who were 6 to 11 months of age (6.1%) than among the recipients of inactivated vaccine in this age group (2.6%, P=0.002).
Conclusions
Among young children, live attenuated vaccine had significantly better efficacy than inactivated vaccine. An evaluation of the risks and benefits indicates that live attenuated vaccine should be a highly effective, safe vaccine for children 12 to 59 months of age who do not have a history of asthma or wheezing. (ClinicalTrials.gov number, NCT00128167.)
Media in This Article
Figure 1
Kaplan–Meier Curves for the Time to the First Culture-Confirmed Report of Influenza in the Two Vaccine Groups.Figure 2
Difference in Rates of Hospitalization between the Two Vaccine Groups, According to Age and the Presence or Absence of a History of Wheezing Illness before Vaccination.Article Activity
- Article
Hospitalization rates for culture-confirmed influenza among young children are similar to those among the elderly, and outpatient visits for confirmed influenza are more frequent among infants and young children than in any other age group.1 For these reasons, U.S. advisory bodies have recently recommended the routine vaccination of all children 6 to 59 months of age with the licensed trivalent inactivated influenza vaccine.2 The implementation of this recommendation will be challenging because of the limited supplies of inactivated vaccine during many influenza seasons,3-5 the modest efficacy of inactivated vaccine in young children,6 and the frequent need to administer the inactivated vaccine by injection concurrent with multiple other parenteral vaccines.
Previous clinical trials of live attenuated trivalent influenza vaccine in young children have shown it to be highly effective.7-9 Live attenuated influenza vaccine showed high efficacy when epidemic influenza viruses were not well matched to the recommended vaccine antigens.7 Initial studies comparing the efficacy of cold-adapted trivalent live attenuated influenza vaccine with trivalent inactivated vaccine have shown the former to be more effective (35 to 53% reduction in the influenza attack rate with live attenuated vaccine, as compared with inactivated vaccine).10,11 Although the safety of live attenuated influenza vaccine was assessed in children in both prospective and database studies,12-15 additional prospective studies of both inactivated vaccine and live attenuated vaccine were needed. In one study,15 but not in others,10,11,16 wheezing events were more frequent among young children given formulations of live attenuated vaccine. The present trial was designed to assess the safety and relative efficacy of live attenuated intranasal influenza vaccine and inactivated vaccine in children 6 to 59 months of age.
Methods
Study Design
The study was proposed by a subgroup of the authors, and the protocol was developed by all the authors in collaboration with an advisory committee. Data were gathered at each study site by the local principal investigator and the local staff. The data were monitored by PPD in the United States and Europe and by Quintiles at the Asian sites. A data and safety monitoring board oversaw the study. The analysis was performed by biostatisticians employed by the sponsor. All authors had complete access to all data and all individual case-report forms, including data on all serious adverse events. All the authors vouch for the accuracy and completeness of the reported data.
The study was conducted at 249 sites (physicians' offices and primary care clinics) in 16 countries: the United States (49% of subjects), 12 countries in Europe and the Middle East (45% of subjects), and 3 countries in Asia (6% of subjects). The protocol and the informed consent forms were approved by the institutional review board at each participating center, and the study was conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Clinical Practice.
After written informed consent had been obtained from a parent or guardian, children 6 to 59 months of age were randomly assigned on a 1:1 basis to receive either live attenuated vaccine or inactivated vaccine with the use of a centrally managed computer-generated randomization schedule. Subjects were stratified according to age on receipt of the first dose, the presence or absence of previous influenza vaccination, the presence or absence of a history of recurrent wheezing (defined as three or more wheezing episodes, each requiring medical follow-up or hospitalization, according to the parent's report or chart review), and country of residence. Children with a history of hypersensitivity to any component of the live attenuated vaccine or the inactivated vaccine were excluded; other exclusion criteria were a known immunosuppressive condition, medically diagnosed or treated wheezing within 42 days before enrollment, a history of severe asthma (as judged by the investigator), body temperature higher than 37.8°C (100°F) measured orally or the equivalent within 3 days before enrollment, and the use of aspirin or salicylate-containing products within 30 days before enrollment. Children with mild or moderate asthma or a history of wheezing (i.e., more than 42 days before enrollment) were included in the trial.
Children who had not previously been vaccinated against influenza were given two doses of the assigned study vaccine; the first dose (dose 1) was administered on day 0 of the trial, and the second dose was administered 28 to 42 days later. Those who had previously been vaccinated against influenza were given only one dose. Subjects who were assigned to receive live attenuated vaccine, which was administered intranasally, also received a concurrent injection of intramuscular saline, and those assigned to receive inactivated vaccine, which was administered intramuscularly, also received a concurrent intranasal mist of saline.
Vaccines and Placebo
The live attenuated intranasal vaccine was a refrigeration-stable (2 to 8°C) formulation of the currently licensed frozen FluMist (LAIV, MedImmune). This vaccine consisted of three cold-adapted reassortant influenza viruses grown in specific pathogen-free chicken eggs. Each dose of vaccine contained approximately 107 fluorescence focus assay units of each of the three strains of the 2004–2005 influenza season, as recommended by the Food and Drug Administration (A/New Caledonia/20/99 [H1N1], A/Wyoming/3/2003 [an A/Fujian/411/2002 (H3N2)–like virus], and B/Jilin/20/2003 [a B/Shanghai/361/2002-like virus]). A total of 0.2 ml of vaccine was administered (0.1 ml into each nostril with the use of an intranasal-spray device).
The licensed inactivated vaccine consisted of the recommended 2004–2005 influenza strains (A/New Caledonia/20/99 [H1N1], A/Wyoming/3/2003 [an A/Fujian/411/2002 (H3N2)–like virus], and B/Jiangsu/10/2003 [a B/Shanghai/361/2002-like virus]), and the vaccine was administered by intramuscular injection, according to the manufacturer's dosing instructions. In the United States and Asia, Fluzone (Aventis Pasteur) was used, and in Europe and the Middle East, Vaxigrip (Aventis Pasteur) was used. Children 6 to 35 months of age received 0.25 ml of intramuscular inactivated vaccine, and those 36 to 59 months of age received 0.5 ml of intramuscular inactivated vaccine.
Intranasal and intramuscular placebos were composed of physiologic saline and were given in a manner identical to the administration of the corresponding study vaccine. The subject, the subject's parent or guardian, the staff at the clinical site who were evaluating the subjects (including the investigators, study nurses, and coordinators), and the clinical, biostatistical, and data-management staff employed by the sponsor were unaware of the treatment assignments. The vaccines and placebos were maintained at 2 to 8°C and were shipped by express courier to the study sites.
Surveillance for Outcomes and Symptoms of Influenza
Parents or guardians recorded local reactions, daily temperatures (oral, axillary, or rectal), systemic adverse events, and concomitant medications on worksheets from the time that dose 1 was administered until 42 days after the administration of the second dose, or until 42 days after dose 1 among subjects who received only one dose. Data on medically significant wheezing and serious adverse events (defined as events that were life-threatening or that resulted in death, hospitalization or prolonged hospitalization, significant disability or incapacity, or another important medical event requiring intervention to prevent one of these outcomes) were collected from the day of dose 1 until the end of the influenza surveillance period, extending through May 31, 2005. Medically significant wheezing was prospectively defined as the presence of wheezing on a physical examination conducted by a health care provider, with a prescription for a daily bronchodilator; respiratory distress; or hypoxemia. Study staff contacted the children's parents or guardians every 7 to 10 days throughout the influenza surveillance period, and if symptoms defined in the study protocol as suggestive of influenza were reported, nasal swabs for viral cultures were obtained either at the study site or at the child's home. Virologic methods are summarized in the Supplementary Appendix (available with the full text of this article at www.nejm.org).
Statistical Analysis
Assuming a 3.0% attack rate in the group that received inactivated vaccine and a 1.8% attack rate in the group that received live attenuated vaccine (relative efficacy rate, 40%) and assuming that sufficient data would be collected for 90% of the children to be included in the according-to-protocol population, we calculated that a sample of 8500 children would provide more than 90% power to demonstrate the superiority of live attenuated vaccine to inactivated vaccine (see the Statistics section in the Supplementary Appendix). The primary end point was the efficacy of live attenuated vaccine, as compared with that of inactivated vaccine, in preventing culture-confirmed influenza-like illness as defined by the Centers for Disease Control and Prevention (CDC), modified to account for the subject's age, caused by well-matched influenza strains. The modified CDC definition of influenza-like illness was an oral temperature of 37.8°C or higher or the equivalent in the presence of cough, sore throat, or runny nose or nasal congestion occurring on the same or consecutive days; the addition of runny nose or nasal congestion to the case definition accounts for the age modification. Culture-positive influenza strains were assessed according to whether the isolated virus was well matched or significantly drifted to the vaccine strains. For detailed information on the statistical methods, see the Supplementary Appendix.
Secondary efficacy end points included the efficacy of live attenuated vaccine, as compared with that of inactivated vaccine, in preventing culture-confirmed influenza-like illness (according to the modified CDC definition) caused by antigenically mismatched influenza viruses and by all influenza viruses. Other efficacy end points included any culture-confirmed symptomatic influenza infection (as distinguished from influenza-like illness that met the modified CDC definition), medically diagnosed acute otitis media with fever and antibiotic use, and medically diagnosed lower respiratory illness, all associated with a positive nasal-swab culture for influenza virus at any time during the interval between the seventh day before the onset of the illness and the seventh day after the end of the illness.
Results
Study Population and Follow-up
From October 20 to October 29, 2004, a total of 8475 children were enrolled (for details on the study populations, see Fig. 1 in the Supplementary Appendix). On average, 34 children (range, 1 to 270; median, 26) underwent randomization at each study site. Safety data were available for 8352 children, 7852 of whom were included in the analysis of the according-to-protocol population. Demographic and other characteristics, including number of days of follow-up, were well balanced between the group that received live attenuated vaccine and the group that received inactivated vaccine (Table 1Table 1
Characteristics and Follow-up of Subjects Included in the Safety Population.). A total of 1880 of the children had previously received an influenza vaccine, and 6472 had not previously been vaccinated. Of those who received dose 1 of the vaccine and were assigned to receive a second dose, 3002 (92.4%) in the live-attenuated-vaccine group and 3034 (94.0%) in the inactivated-vaccine group received both doses. Overall on entry into the trial, 5.7% of the children in each group had underlying medical conditions, 21% had a history of any wheezing (as reported by a parent, guardian, or health care provider), and 6% had recurrent wheezing. More than 20,000 nasal specimens were cultured during the surveillance period (2.4 cultures per child).Efficacy
Kaplan–Meier curves for the time of the acquisition of a culture-confirmed influenza-like illness (according to the modified CDC definition) in the two groups are shown in Figure 1Figure 1
Kaplan–Meier Curves for the Time to the First Culture-Confirmed Report of Influenza in the Two Vaccine Groups., and the attack rates are summarized in Table 2Table 2
Influenza Attack Rates in the According-to-Protocol Population.. There were 185 (54.9%) fewer cases of influenza in the live-attenuated-vaccine group (153 cases; attack rate, 3.9%) than in the inactivated-vaccine group (338 cases; attack rate, 8.6%) (P<0.001). According to the virus subtype, vaccination with live attenuated vaccine resulted in 89.2% fewer cases of influenza A/H1N1 (P<0.001), 79.2% fewer cases of influenza A/H3N2 (P<0.001), and 16.1% fewer cases of influenza B (P=0.19). The live attenuated vaccine was significantly more protective against both well-matched and mismatched influenza A viruses (Table 2). All isolates of H1N1 virus were regarded as antigenically matched. All isolates of H3N2 virus were antigenically mismatched. In contrast, the circulating B strains were divided into two lineages, Yamagata-like (strains that were antigenically matched and mismatched to vaccine) and Victoria-like (antigenically mismatched to vaccine). Although the difference was not significant, live attenuated vaccine showed a relative efficacy of 27%, as compared with inactivated vaccine, against the matched B strains, but there was no significant difference in efficacy against mismatched B strains.For all culture-confirmed symptomatic influenza, the overall attack rates were 5.0% in the group that received live attenuated vaccine and 10.0% in the group that received inactivated vaccine, with a 50.6% reduction in the live-attenuated-vaccine group, as compared with the inactivated-vaccine group (P<0.001). Significant reductions were also seen in the overall attack rates of acute otitis media and lower respiratory illness associated with positive influenza cultures, as diagnosed by a health care provider, with a relative efficacy in the live-attenuated-vaccine group of 50.6% (P=0.004) and 45.9% (P=0.046), respectively (see Table 1 in the Supplementary Appendix).
Adverse Events
The incidence of pain, redness, and swelling at the injection site, with most instances reported as mild to moderate in severity, was higher in the group that received inactivated vaccine than in the group that received intramuscular placebo. Among subjects being vaccinated for the first time, 57.0% of those receiving intramuscular placebo and 46.3% of those receiving intranasal placebo had a runny or stuffy nose within 10 days after vaccination. With fever defined as a temperature of more than 37.8°C, fever occurred in 5.4% of the live-attenuated-vaccine group and 2.0% of the inactivated-vaccine group on day 2 after receipt of dose 1 of vaccine (P<0.001). With the use of a higher temperature cutoff (fever defined as 38.9°C [>102°F]), the incidence of fever was low (<1% on day 2, after receipt of dose 1) in both vaccine groups. No significant differences in fever were found between the two groups after the second dose (see Fig. 2 in the Supplementary Appendix).
The rates of medically significant wheezing during the 42-day period after each dose of vaccine are shown in Table 3Table 3
Incidence in the Safety Population of Medically Significant Wheezing within 42 Days after Receiving Vaccine.. Overall, there was no significant difference in medically significant wheezing between the two groups. In previously unvaccinated children, after dose 1, there were 74 cases of medically significant wheezing (2.3%) among children given live attenuated vaccine, as compared with 48 cases (1.5%) among those given inactivated vaccine, with a significant adjusted rate difference of 0.77% (95% confidence interval [CI], 0.12 to 1.46). The increase in medically significant wheezing was seen primarily during the second, third, and fourth weeks after vaccination (Fig. 3 in the Supplementary Appendix). Among previously unvaccinated children 24 months of age or older, there was no significant difference in the rates of medically significant wheezing between the two groups. Among those younger than 24 months of age, 55 children (3.2%) in the live-attenuated-vaccine group and 34 children (2.0%) in the inactivated-vaccine group had medically significant wheezing after receipt of dose 1, with an adjusted difference of 1.18 (95% CI, 0.13 to 2.29). The difference in the incidence of medically significant wheezing was seen primarily in children less than 12 months of age (see Fig. 4 in the Supplementary Appendix), with 12 more episodes of wheezing after dose 1 in children in this age group who received live attenuated vaccine than in those who received inactivated vaccine (3.8% vs. 2.1%, P=0.08).A review of hospital records for children less than 24 months of age who were hospitalized with medically significant wheezing indicated a similar severity of illness among those receiving live attenuated vaccine and those receiving inactivated vaccine and in the duration of stay in the hospital, associated diagnoses, and treatment (Tables 2 and 3 in the Supplementary Appendix). Beyond 42 days after vaccination, the rates of medically significant wheezing did not differ significantly between the two groups among children less than 24 months of age (7.6% in the live-attenuated-vaccine group and 7.1% in the inactivated-vaccine group). The proportion of those less than 24 months of age who had medically significant wheezing within 42 days after vaccination and who had at least one additional medically significant wheezing episode during the study period was similar in the two groups (32% in the live-attenuated-vaccine group and 28% in the inactivated-vaccine group); the proportion of these children who had two or more additional medically significant wheezing episodes was 4.3% and 5.3%, respectively.
The incidence of serious adverse events in the two groups was similar (136 in the live-attenuated-vaccine group and 128 in the inactivated-vaccine group) (Table 4Table 4
Medically Significant Wheezing, Serious Adverse Events, and Rates of Hospitalization According to Age Group, through 180 Days after the Last Dose of Vaccine.). Six serious adverse events in the live-attenuated-vaccine group (bronchiolitis in two children, and asthma exacerbation, wheezing, acute gastroenteritis, and reactive airway disease in one child each) and five in the inactivated-vaccine group (pneumonia, wheezing, febrile convulsion, febrile convulsion and pneumonia, and viral gastroenteritis in one child each) were considered by the investigator, who was unaware of the treatment assignments, to be potentially related to the study vaccine. One death occurred in each vaccine group — one because of aspiration of a foreign body and one because of a house fire. New diagnoses of chronic diseases assessed within 180 days after the last dose of vaccine were infrequent in the two groups, with overall incidence rates of 1.7% in the live-attenuated-vaccine group and 1.3% in the inactivated-vaccine group.A post hoc analysis for the study period through 180 days after the last dose of vaccine showed that children 6 to 11 months of age were hospitalized for any cause at a higher rate in the live-attenuated-vaccine group than in the inactivated-vaccine group (6.1% vs. 2.6%; difference in rate, 3.5% [95% CI, 1.4 to 5.8]) (Figure 2Figure 2
Difference in Rates of Hospitalization between the Two Vaccine Groups, According to Age and the Presence or Absence of a History of Wheezing Illness before Vaccination. and Table 4, and Table 4 in the Supplementary Appendix). The rate of hospitalization for respiratory diagnoses in this age group was 3.2%, as compared with 1.2% in the two groups, respectively (absolute difference, 2.0% [95% CI, 0.5 to 3.8]). The differences in hospitalization rates among children 12 to 23 months of age (3.2% in the live-attenuated-vaccine group and 3.5% in the inactivated-vaccine group) and among children 24 to 59 months of age were not significant. Although not statistically significant, there was a trend toward a higher rate of hospitalization for any cause among children receiving live attenuated vaccine who were 6 to 47 months of age and had a history of wheezing than among those receiving inactivated vaccine who were in the same age group and had a history of wheezing. Among children 12 to 59 months of age who did not have a history of wheezing, the rates of hospitalization for any cause were lower in the live-attenuated-vaccine group than in the inactivated-vaccine group (P=0.07).Discussion
Many believe that the successful control of annual influenza epidemics depends on vaccinating a high proportion of children.16-18 As U.S. public health authorities move toward this goal, highly effective vaccines are needed, including vaccines with efficacy against antigenically drifted influenza strains. The live attenuated influenza vaccine we used has many of the characteristics that are desirable for the control of epidemic influenza. In addition to its high acceptability because of the mode of administration, the significantly higher efficacy of this live attenuated vaccine than of the licensed inactivated vaccine suggests that it can play an important role in the control of influenza. This higher efficacy was seen not only for well-matched strains but also for viruses that were antigenically drifted from the antigen in the vaccine.
Some earlier studies have suggested the potential for wheezing in young children after receipt of live attenuated influenza vaccine,15 whereas others have not.10,16 Our comprehensive, prospective safety study showed an increased risk of medically significant wheezing (within 42 days after vaccination) among recipients of live attenuated vaccine who were younger than 12 months of age. The pathogenesis of wheezing in some children given live attenuated vaccine remains unknown, although in our study, the wheezing developed after the peak of viral replication and at the time when immune responses to the viruses are expected — that is, during weeks 2, 3, and 4 after vaccination.
The incidence of serious adverse events did not differ significantly between the two groups. However, in post hoc analyses, rates of hospitalization for any cause among infants 6 to 11 months of age were significantly higher in the live-attenuated-vaccine group than in the inactivated-vaccine group. In addition, higher, but not significantly higher, rates of hospitalization were observed among children in the age groups of 12 to 23 months, 24 to 35 months, and 36 to 47 months who had a history of wheezing illness before entering the study. These observations require further study. Children 12 months of age or older who had no history of wheezing illness before vaccination and who received live attenuated vaccine had lower rates of hospitalization for any cause during the study than those who received inactivated vaccine. On the basis of our results, the risk–benefit ratio for live attenuated vaccine appears favorable among children 12 to 47 months of age who have no history of wheezing.
Until additional data are available, the observations related to medically significant wheezing and rates of hospitalization will restrict the use of live attenuated vaccine in children younger than 1 year and in children 12 to 47 months of age who have a history of asthma or wheezing. Additional studies to determine the optimal use of both vaccines in infants and young children are warranted. The high influenza attack rate among children in the inactivated-vaccine group who were less than 12 months of age and had a history of wheezing (14%) suggests that inactivated vaccine has low efficacy in this group. Further studies might show whether an initial dose of inactivated vaccine followed by live attenuated vaccine would provide optimal protection for children younger than 1 year of age while also ensuring maximum vaccine safety.
Supported by MedImmune.
Dr. Belshe reports receiving research support from Merck and MedImmune and consulting fees or lecture fees from MedImmune, Merck, Novartis, GlaxoSmithKline, and Sanofi; Dr. Edwards, research support from Sanofi Pasteur, Vaxgen, Merck, and Nabi and consulting fees from MedImmune; Dr. Vesikari, consulting fees or lecture fees from MedImmune, Merck, and GlaxoSmithKline; and Dr. Black, research support from Chiron, GlaxoSmithKline, MedImmune, and Merck and consulting fees or lecture fees from Chiron, MedImmune, and Merck. Drs. Walker, Kemble, and Connor and Ms. Hultquist are employees of MedImmune. No other potential conflict of interest relevant to this article was reported.
We thank I. Cho, P.M. Mendelman, C. Hessel, K. Coelingh, C. Dingivan, R. Hernandez, C. Knightly, C. Frickleton, Y. Zhou, and T. Yi for their contributions to this study; S. Stoughton for assistance in writing the study report; and the clinical research staff at all the participating sites, all the children and their families who participated in the study, and the members of the data-monitoring committee — J. Treanor, J. Modlin, and W. Blackwelder — for their time and effort.
Source Information
From the Saint Louis University Health Sciences Center, St. Louis (R.B.B.); Vanderbilt University School of Medicine, Nashville (K.M.E.); University of Tampere Medical School, Tampere, Finland (T.V.); Kaiser Permanente Vaccine Study Center, Oakland, CA (S.V.B.); and MedImmune, Gaithersburg, MD (R.E.W., M.H., G.K., E.M.C.).
Address reprint requests to Dr. Belshe at the Division of Infectious Diseases and Immunology, Saint Louis University School of Medicine, 3635 Vista Ave. (FDT-8N), St. Louis, MO 63110, or at belsherb@slu.edu.
Participants in the Cold-Adapted Live Attenuated Influenza Vaccine, Trivalent (CAIV-T) Comparative Efficacy Study are listed in the Appendix.
Appendix
Participants in the CAIV-T Comparative Efficacy Study Group were as follows (members of the Advisory Committee are marked with an asterisk): Belgium: W. Lipschutz, A. Malfroot, E. Schatteman, V. Vanbelle, C. Vandermeulen, F. Van Kerckhoven, A. Vertruyen. Czech Republic: J. Biolek, H. Honomichlova, P. Mokros, M. Mokrosova. Finland: A. Hanni, T. Karppa, A. Karvonen, T. Korhonen, J. Immonen, N. Lindblad, J Ojanpera, S. Parry, P. Riikonen, A. Salomäki, T. Vesikari.* Germany: K. Deichmann, P. Habermehl, G. Hein, H. Sengespeik, I. Tichmann-Schumann. Greece: C. Katsardis, J. Kavaliotis, A. Constantopoulos, P. Nikolaidou, V. Syriopoulou, J. Tsanakas. Hong Kong: K. Huen, Y. Hui, Y. Lau, D. Ng, L. So, R. Sung. Iceland: G. Jonasson. Israel: S. Arnon, A. Bahir, M. Bendet, A. Cohen, S. Gross, D. Hornik, H. Kirstal, Y. Laks, M. Levy, D. Paz, O. Poznanski, S. Rigler, Y. Rosen, Y. Shag, Y. Uziel, A. Yarom, E. Zinder Koziel. Italy: G. Bona, R. Cutrera, N. Principi, S. Esposito, P. Marchisio. Korea: K. Ahn, S. Cha, D. Kim, Y. Kim. Lebanon: G. Dbaibo, R. Sacy. Spain: L. Antón Crespo, J. Baldó, J. Ferres, M. Garcés, M. García, A. Jubert, C. Landaluce, A. Martínez-Roig, M. Muñoz del Barrio, V. Planelles, I. Sorribes, I. Ubeda. Sweden: C. Flodmark, L. Gothefors, B. Granström, S. Klaesson, C. Penno, L. Stenhammar, M. Wedenberg. Taiwan: P. Chen, N. Chiu, L. Huang,* Y. Huang, C. Lin. United Kingdom: M. Blagden, B. Bodalia, R. Brownlie, R. Cook, A. Egerton, C. Fletcher, M. Garala, A. George, A. Graham, T. Hall, J. Ham, D. Haworth, R. Lal-Sarin, M. McCaughey, C. McKinnon,* A. Menezes, P. Shearer, B. Silvert, H. Simpson, A. Takhar. United States: G. Adams, W. Andrews, L. Angles, C. Arango, B. Asmar, A. Atz, R. Bain, B. Baker, O. Basta, M. Baz, J. Bellanti, D. Bernstein,* S. Black,* S. Block,* G. Bottenfield, P. Bristol, R. Carson, M. Castleberry, S. Christensen, E. Cockrum, M. Cox, C. Crismon, K. Davis, P. Dennehy, F. Eder, K. Edwards,* V. Elinoff, I. Emanuel, B. Essink, G. Fennelly, C. Fisher, J. Frey, M. Gaglani, R. Gaona, F. Garner, S. Gawchik, W. Geffen, R. Geller, I. Graham, C. Hall, F. Hampel, J. Harris, C. Harrison, F. Hayden,* L. Hazan, C. Hebert, F. Henderson, D. Henry, D. Herrington, D. Hurley, K. Jackson, D. Johnson, W. Johnston, E. Kairis, M. Kaliner,* H. Keyserling, L. Krilov, C. LaForce, M. Lauret, J. Leader, H. Lesicka, M. Levin, J. Ley, C. Lively, F. Mabry, C. Marchant, D. Matson, L. Meloy, S. Melton, D. Moore, E. Morsi, J. Moy, M. Mufson, A. Nayak, N. Neu, J. Nutman, R. Ohnmacht, A. Palazzo, B. Patel, G. Patel, M. Pichichero, K. Reisinger,* R. Rhoades, G. Rockower, J. Romero, T. Schechtman, R. Schwartz, W. Seger, S. Senders, J. Shepard, L. Sher, P. Shurin, P. Silas, K. Sitz, C. Smith, W. Spencer, M. Sperling, K. Stevenson, M. Taghadosi, J. Tillisch, C. Toledo, T. Twogood, E. Wald, W. Warren, R. Wasserman, R. Watson, L. Weiner, J. Wise, R. Yogev.
- References
References
1
Poehling KA ,Edwards KM ,Weinberg GA , et al. The underrecognized burden of influenza in young children. N Engl J Med 2006;355:31-40
Full Text | Web of Science | Medline2
Smith NM ,Bresee JS ,Shay DK ,Uyeki TM ,Cox NJ ,Strikas RA . Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1-42[Erratum, MMWR Morb Mortal Wkly Rep 2006;55:800.]
Medline3
Delayed supply of influenza vaccine and adjunct ACIP influenza vaccine recommendations for the 2000-01 influenza season. MMWR Morb Mortal Wkly Rep 2000;49:619-622
Medline4
Delayed influenza vaccine availability for 2001-02 season and supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2001;50:582-585
Medline5
Interim influenza vaccination recommendations -- 2004-05 influenza season. MMWR Morb Mortal Wkly Rep 2004;53:1183-1184
Medline6
Zangwill KM ,Belshe RB . Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J 2004;23:189-197
CrossRef | Web of Science | Medline7
Belshe RB ,Gruber WC ,Mendelman PM , et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000;136:168-175
CrossRef | Web of Science | Medline8
Belshe RB ,Mendelman PM ,Treanor J , et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998;338:1405-1412
Full Text | Web of Science | Medline9
Belshe R, Maassab H, Mendelman P. Live influenza virus vaccine. In: Plotkin S, Orenstein W, eds. Vaccines. 4th ed. Philadelphia: Saunders, 2004:371-88.
10
Ashkenazi S ,Vertruyen A ,Aristegui J , et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006;25:870-879
CrossRef | Web of Science | Medline11
Fleming DM ,Crovari P ,Wahn U , et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006;25:860-869
CrossRef | Web of Science | Medline12
Belshe RB ,Mendelman PM . Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent. Immunol Allergy Clin North Am 2003;23:745-767
CrossRef | Web of Science | Medline13
Belshe R ,Lee M-S ,Walker RE ,Stoddard J ,Mendelman PM . Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines 2004;3:643-654
CrossRef | Medline14
Glezen WP . Cold-adapted, live attenuated influenza vaccine. Expert Rev Vaccines 2004;3:131-139
CrossRef | Medline15
Bergen R ,Black S ,Shinefield H , et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004;23:138-144
CrossRef | Web of Science | Medline16
Piedra PA ,Gaglani MJ ,Riggs M , et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 2005;116:e397-e407
CrossRef | Web of Science | Medline17
Longini IM Jr ,Halloran ME . Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol 2005;161:303-306
CrossRef | Web of Science | Medline18
Reichert TA ,Sugaya N ,Fedson DS ,Glezen WP ,Simonsen L ,Tashiro M . The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001;344:889-896
Full Text | Web of Science | Medline
- Citing Articles (157)
Citing Articles
1
(2012) Influenza Vaccine in Young Children. New England Journal of Medicine 366:4, 383-384
Full Text2
Anu Cherukuri, Esteban Servat, Jennifer Woo. (2012) Vaccine-specific antibody secreting cells are a robust early marker of LAIV-induced B-cell response in ferrets. Vaccine 30:2, 237-246
CrossRef3
Christopher S. Ambrose, Xionghua Wu, Markus Knuf, Peter Wutzler. (2012) The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies. Vaccine 30:5, 886-892
CrossRef4
S. E. Ohmit, J. G. Petrie, R. T. Cross, E. Johnson, A. S. Monto. (2011) Influenza Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection. Journal of Infectious Diseases 204:12, 1879-1885
CrossRef5
J Kevin Yin, Monica M Lahra, Mary Iskander, Stephen B Lambert, Leon Heron, Michael D Nissen, Laura Rost, Jennifer Murphy, Theo P Sloots, Robert Booy. (2011) Pilot study of influenza vaccine effectiveness in urban Australian children attending childcare. Journal of Paediatrics and Child Health 47:12, 857-862
CrossRef6
N. B. Halasa. (2011) Make New Friends, But Keep the Old: Influenza Vaccines in Children With Cancer. Journal of Infectious Diseases 204:10, 1471-1474
CrossRef7
S. Carr, K. J. Allison, L.-A. Van De Velde, K. Zhang, E. Y. English, A. Iverson, N. C. Daw, S. C. Howard, F. Navid, C. Rodriguez-Galindo, J. Yang, E. E. Adderson, J. A. McCullers, P. M. Flynn. (2011) Safety and Immunogenicity of Live Attenuated and Inactivated Influenza Vaccines in Children With Cancer. Journal of Infectious Diseases 204:10, 1475-1482
CrossRef8
Barbara Michiels, Frans Govaerts, Roy Remmen, Etienne Vermeire, Samuel Coenen. (2011) A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine 29:49, 9159-9170
CrossRef9
Joan Puig-Barberà, Silvia Pérez-Vilar, Javier Díez-Domingo. (2011) MF59™-adjuvanted seasonal influenza vaccine in young children. Expert Review of Vaccines 10:11, 1519-1528
CrossRef10
Christopher S. Ambrose, Tingting Yi, Judith Falloon. (2011) An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years. Influenza and Other Respiratory Viruses 5:6, 389-397
CrossRef11
Vesikari, Timo, Knuf, Markus, Wutzler, Peter, Karvonen, Aino, Kieninger-Baum, Dorothee, Schmitt, Heinz-Josef, Baehner, Frank, Borkowski, Astrid, Tsai, Theodore F., Clemens, Ralf, . (2011) Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children. New England Journal of Medicine 365:15, 1406-1416
Full Text12
Regina Scherließ. (2011) Delivery of antigens used for vaccination: recent advances and challenges. Therapeutic Delivery 2:10, 1351-1368
CrossRef13
J. S. Bradley, C. L. Byington, S. S. Shah, B. Alverson, E. R. Carter, C. Harrison, S. L. Kaplan, S. E. Mace, G. H. McCracken, M. R. Moore, S. D. St Peter, J. A. Stockwell, J. T. Swanson. (2011) The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clinical Infectious Diseases 53:7, e25-e76
CrossRef14
Susanna Esposito, Nicola Principi. (2011) Different influenza vaccine formulations and adjuvants for childhood influenza vaccination. Vaccine 29:43, 7535-7541
CrossRef15
Terho Heikkinen, Santtu Heinonen. (2011) Effectiveness and safety of influenza vaccination in children: European perspective. Vaccine 29:43, 7529-7534
CrossRef16
Susanna Esposito, Cristina Daleno, Irene Picciolli, Laura Tagliaferri, Alessia Scala, Giulia Prunotto, Valentina Montinaro, Carlotta Galeone, Nicola Principi. (2011) Immunogenicity and safety of intradermal influenza vaccine in children. Vaccine 29:44, 7606-7610
CrossRef17
D. F. Hoft, E. Babusis, S. Worku, C. T. Spencer, K. Lottenbach, S. M. Truscott, G. Abate, I. G. Sakala, K. M. Edwards, C. B. Creech, M. A. Gerber, D. I. Bernstein, F. Newman, I. Graham, E. L. Anderson, R. B. Belshe. (2011) Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children. Journal of Infectious Diseases 204:6, 845-853
CrossRef18
Matthew D. White, Catharine M. Bosio, Barry N. Duplantis, Francis E. Nano. (2011) Human body temperature and new approaches to constructing temperature-sensitive bacterial vaccines. Cellular and Molecular Life Sciences 68:18, 3019-3031
CrossRef19
Bruce Y. Lee, Julie H. Y. Tai, Sarah M. McGlone, Rachel R. Bailey, Angela R. Wateska, Shanta M. Zimmer, Richard K. Zimmerman, Michael M. Wagner. (2011) The potential economic value of a ‘universal’ (multi-year) influenza vaccine. Influenza and Other Respiratory Virusesno-no
CrossRef20
Kathryn A. Radigan, Richard G. Wunderink. (2011) Epidemic Viral Pneumonia and Other Emerging Pathogens. Clinics in Chest Medicine 32:3, 451-467
CrossRef21
W.E.P. Beyer, J.J.P. Nauta, A.M. Palache, K.M. Giezeman, A.D.M.E. Osterhaus. (2011) Immunogenicity and safety of inactivated influenza vaccines in primed populations: A systematic literature review and meta-analysis. Vaccine 29:34, 5785-5792
CrossRef22
Christelle Liard, Séverine Munier, Mauricio Arias, Alix Joulin-Giet, Olivia Bonduelle, Darragh Duffy, Robin J. Shattock, Bernard Verrier, Behazine Combadière. (2011) Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine 29:37, 6379-6391
CrossRef23
Erica Y. Chung, Vincent W. Chiang. (2011) Influenza Vaccination, Diagnosis, and Treatment in Children. Pediatric Emergency Care 27:8, 760-769
CrossRef24
Natalie J. Carter, Monique P. Curran. (2011) Live Attenuated Influenza Vaccine (FluMist®; Fluenz™). Drugs 71:12, 1591-1622
CrossRef25
Steffen Borrmann, Kai Matuschewski. (2011) Protective immunity against malaria by ‘natural immunization’: a question of dose, parasite diversity, or both?. Current Opinion in Immunology 23:4, 500-508
CrossRef26
Angela Henderson, Katie Propst, Ross Kedl, Steven Dow. (2011) Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity. Vaccine 29:32, 5304-5312
CrossRef27
Patricia Tennis, Seth L. Toback, Elizabeth Andrews, Lisa J. McQuay, Christopher S. Ambrose. (2011) A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years. Vaccine 29:31, 4947-4952
CrossRef28
E Richard Moxon, Claire-Anne Siegrist. (2011) The next decade of vaccines: societal and scientific challenges. The Lancet 378:9788, 348-359
CrossRef29
Fatimah S. Dawood, Alicia M. Fry, Charung Muangchana, Wiwan Sanasuttipun, Henry C. Baggett, Supamit Chunsuttiwat, Susan A. Maloney, James Mark Simmerman. (2011) A method for estimating vaccine-preventable pediatric influenza pneumonia hospitalizations in developing countries: Thailand as a case study. Vaccine 29:26, 4416-4421
CrossRef30
Saleem Basha, Staci Hazenfeld, Rebecca C. Brady, Ramu A. Subbramanian. (2011) Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin. Human Immunology 72:6, 463-469
CrossRef31
Raburn M. Mallory, Tingting Yi, Christopher S. Ambrose. (2011) Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6–59 months of age. Vaccine 29:26, 4322-4327
CrossRef32
Seth L. Toback, John Herley, Laurel Edelman, Christopher S. Ambrose. (2011) Trends in US pediatric influenza vaccination from 2006 to 2010 among children with private insurance. Vaccine 29:25, 4225-4229
CrossRef33
Emuella M. Flood, Kellie J. Ryan, Matthew D. Rousculp, Kathleen M. Beusterien, Stan L. Block, Matthew C. Hall, Parthiv J. Mahadevia. (2011) A survey of children's preferences for influenza vaccine attributes. Vaccine 29:26, 4334-4340
CrossRef34
Natasha Halasa, Janet A. Englund, Sharon Nachman, Geoffrey A. Weinberg, Victor C. Huber, Kim Allison, Filip Dubovsky, Tingting Yi, Jonathan A. McCullers, Patricia M. Flynn. (2011) Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine 29:24, 4110-4115
CrossRef35
Nicola Principi, Susanna Esposito, Paola Marchisio. (2011) Present and future of influenza prevention in pediatrics. Expert Opinion on Biological Therapy 11:5, 641-653
CrossRef36
Barry N. Duplantis, Catherine M. Bosio, Francis E. Nano. (2011) Temperature-sensitive bacterial pathogens generated by the substitution of essential genes from cold-loving bacteria: potential use as live vaccines. Journal of Molecular Medicine 89:5, 437-444
CrossRef37
D. Floret. (2011) Vaccination contre la grippe : les recommandations sont-elles susceptibles d’évoluer en France ?. Archives de Pédiatrie 18:5, H166-H167
CrossRef38
Susanna Esposito, Paola Marchisio, Rossana Tenconi, Nicola Principi. (2011) Antibiotic treatment of acute otitis media in pediatrics. Future Microbiology 6:5, 485-488
CrossRef39
Kunal Aggarwal, Frank Jing, Luis Maranga, Jonathan Liu. (2011) Bioprocess optimization for cell culture based influenza vaccine production. Vaccine 29:17, 3320-3328
CrossRef40
Helen Petousis-Harris, Tracey Poole, Robert Booy, Nikki Turner. (2011) Fever following administration of two inactivated influenza vaccines—A survey of parents of New Zealand infants and children 5 years of age and under. Vaccine 29:16, 2933-2937
CrossRef41
Jenish R. Patel, Keyur P. Vora, Shashank Tripathi, Hui Zeng, Terrence M. Tumpey, Jacqueline M. Katz, Suryaprakash Sambhara, Shivaprakash Gangappa. (2011) Infection of Lung Epithelial Cells with Pandemic 2009 A(H1N1) Influenza Viruses Reveals Isolate-Specific Differences in Infectivity and Host Cellular Responses. Viral Immunology 24:2, 89-99
CrossRef42
E. Kathryn Miller, Logan Dumitrescu, Chelsea Cupp, Stacy Dorris, Sallee Taylor, Robert Sparks, Diane Fawkes, Virginia Frontiero, Anne M. Rezendes, Colin Marchant, Kathryn M. Edwards, Dana C. Crawford. (2011) Atopy history and the genomics of wheezing after influenza vaccination in children 6–59 months of age. Vaccine 29:18, 3431-3437
CrossRef43
Christopher S. Ambrose, Myron J. Levin, Robert B. Belshe. (2011) The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza and Other Respiratory Viruses 5:2, 67-75
CrossRef44
Stan L. Block, Terho Heikkinen, Seth L. Toback, Wei Zheng, Christopher S. Ambrose. (2011) The Efficacy of Live Attenuated Influenza Vaccine Against Influenza-associated Acute Otitis Media in Children. The Pediatric Infectious Disease Journal 30:3, 203-207
CrossRef45
Masahiko Katayose, Mitsuaki Hosoya, Takashi Haneda, Hideo Yamaguchi, Yukihiko Kawasaki, Masatoki Sato, Peter F. Wright. (2011) The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons. Vaccine 29:9, 1844-1849
CrossRef46
James E. Crowe. 2011. Prevention of Fetal and Early Life Infections Through Maternal–Neonatal Immunization. , 1212-1230.
CrossRef47
Luigi Buonaguro, Bali Pulendran. (2011) Immunogenomics and systems biology of vaccines. Immunological Reviews 239:1, 197-208
CrossRef48
Katie Harris, Rebecca Ream, Jin Gao, Maryna C Eichelberger. (2011) Intramuscular immunization of mice with live influenza virus is more immunogenic and offers greater protection than immunization with inactivated virus. Virology Journal 8:1, 251
CrossRef49
Ramu A. Subbramanian, Saleem Basha, Mohamed T. Shata, Rebecca C. Brady, David I. Bernstein. (2010) Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. Vaccine 28:52, 8258-8267
CrossRef50
Zichria Zakay-Rones. (2010) Human influenza vaccines and assessment of immunogenicity. Expert Review of Vaccines 9:12, 1423-1439
CrossRef51
Cuc H. Tran, Josephine McElrath, Patricia Hughes, Kathleen Ryan, Jean Munden, Joan B. Castleman, Jackie Johnson, Randell Doty, Dallas R. McKay, Jim Stringfellow, Rosalee A. Holmes, Paul D. Myers, Parker A. Small, J. Glenn Morris. (2010) Implementing a Community-Supported School-Based Influenza Immunization Program. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 8:4, 331-341
CrossRef52
Carlos G. Grijalva, Yuwei Zhu, Lone Simonsen, Marie R. Griffin. (2010) Establishing the baseline burden of influenza in preparation for the evaluation of a countywide school-based influenza vaccination campaign. Vaccine 29:1, 123-129
CrossRef53
Suzanne L Epstein, Graeme E Price. (2010) Cross-protective immunity to influenza A viruses. Expert Review of Vaccines 9:11, 1325-1341
CrossRef54
D.M.W. Zaiss, C.J.P. Boog, W. van Eden, A.J.A.M. Sijts. (2010) Considerations in the design of vaccines that induce CD8 T cell mediated immunity. Vaccine 28:49, 7716-7722
CrossRef55
Adriana Weinberg, Lin-Ye Song, Robert Walker, Maria Allende, Terence Fenton, Julie Patterson-Bartlett, Sharon Nachman, George Kemble, Ting-Ting Yi, Patricia Defechereux, Diane Wara, Jennifer S Read, Myron Levin. (2010) Anti-Influenza Serum and Mucosal Antibody Responses After Administration of Live Attenuated or Inactivated Influenza Vaccines to HIV-Infected Children. JAIDS Journal of Acquired Immune Deficiency Syndromes 55:2, 189-196
CrossRef56
Guillermina A Melendi, Silvina Coviello, Niranjan Bhat, Johanna Zea-Hernandez, Fausto M Ferolla, Fernando P Polack. (2010) Breastfeeding is associated with the production of type I interferon in infants infected with influenza virus. Acta Paediatrica 99:10, 1517-1521
CrossRef57
Harry F. Hull, Heidi OʼConnor. (2010) Optimizing Protection Against Influenza in Children Eligible for the Vaccine for Children Program. The Pediatric Infectious Disease Journal 29:10, 910-914
CrossRef58
Steven M. Smith, John G. Gums. (2010) Antivirals for Influenza. Pediatric Drugs 12:5, 285-299
CrossRef59
Christopher S. Ambrose, Xionghua Wu, Robert B. Belshe. (2010) The Efficacy of Live Attenuated and Inactivated Influenza Vaccines in Children as a Function of Time Postvaccination. The Pediatric Infectious Disease Journal 29:9, 806-811
CrossRef60
Bert E Johansson, Maryna C Eichelberger. (2010) Influenza: a unique problem in vaccination. Future Virology 5:5, 651-664
CrossRef61
Arnold S. Monto. (2010) Seasonal influenza vaccinations: specialized products for different target groups. Vaccine 28, D14-D23
CrossRef62
Susanna Esposito, Paola Marchisio, Filippo Ansaldi, Sonia Bianchini, Michela Pacei, Elena Baggi, Daria Trabattoni, Giancarlo Icardi, Nicola Principi. (2010) A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6–35 months. Vaccine 28:38, 6137-6144
CrossRef63
Romina Libster, Kathryn M. Edwards. (2010) The Necessity of Influenza Vaccination in Children. Pediatric Annals 39:8, 490-496
CrossRef64
B. N. Duplantis, M. Osusky, C. L. Schmerk, D. R. Ross, C. M. Bosio, F. E. Nano. (2010) Essential genes from Arctic bacteria used to construct stable, temperature-sensitive bacterial vaccines. Proceedings of the National Academy of Sciences 107:30, 13456-13460
CrossRef65
Chin-Fen Yang, Robert B. Belshe, George Kemble, Eyun Song, Dan Ye, Brandon Liang, Tingting Yi, Christopher S. Ambrose, Kathy Coelingh, Robert E. Walker. (2010) Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine. Vaccine 28:31, 5128-5134
CrossRef66
C. Weil-Olivier. (2010) Vaccin vivant atténué par voie nasale contre la grippe. Archives de Pédiatrie 17:6, 904-905
CrossRef67
Robert B. Belshe, Seth L. Toback, Tingting Yi, Christopher S. Ambrose. (2010) Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza and Other Respiratory Viruses 4:3, 141-145
CrossRef68
Althaf I. Hussain, Melissa Cordeiro, Elizabeth Sevilla, Jonathan Liu. (2010) Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: In vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 28:22, 3848-3855
CrossRef69
Wei Zhu, Brandon W. Higgs, Chris Morehouse, Katie Streicher, Christopher S. Ambrose, Jennifer Woo, George W. Kemble, Bahija Jallal, Yihong Yao. (2010) A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children. Vaccine 28:16, 2865-2876
CrossRef70
Neetu Singh, Aseem Pandey, Suresh K. Mittal. (2010) Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert Reviews in Molecular Medicine 12,
CrossRef71
Jonathan P Wong, Mary E Christopher, Satya Viswanathan, Glen Schnell, Xiaojiang Dai, Donald Van Loon, Eric R Stephen. (2010) Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza. Expert Review of Respiratory Medicine 4:2, 171-177
CrossRef72
Robert B. Belshe, Kathleen Coelingh, Christopher S. Ambrose, Jennifer C. Woo, Xionghua Wu. (2010) Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 28:9, 2149-2156
CrossRef73
Peter C. Austin, Andrea Manca, Merrick Zwarenstein, David N. Juurlink, Matthew B. Stanbrook. (2010) A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals. Journal of Clinical Epidemiology 63:2, 142-153
CrossRef74
G. D. Deans, H. G. Stiver, J. E. McElhaney. (2010) Influenza vaccines provide diminished protection but are cost-saving in older adults. Journal of Internal Medicine 267:2, 220-227
CrossRef75
Lucy Chai See Lum, Charissa Fay Borja-Tabora, Robert F. Breiman, Timo Vesikari, Benjamin P. Sablan, Oh Moh Chay, Taweewong Tantracheewathorn, Heinz-Josef Schmitt, Yu-Lung Lau, Piyaporn Bowonkiratikachorn, John S. Tam, Bee Wah Lee, Kah Kee Tan, Jerzy Pejcz, Sungho Cha, Maricruz Gutierrez-Brito, Petras Kaltenis, Andre Vertruyen, Hanna Czajka, Jurgis Bojarskas, W. Abdullah Brooks, Sheau-Mei Cheng, Ruth Rappaport, Sherryl Baker, William C. Gruber, Bruce D. Forrest. (2010) Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 28:6, 1566-1574
CrossRef76
&NA;. (2010) Seasonal Trivalent Influenza Vaccine for 2009–2010. Obstetrics & Gynecology 115:1, 174-176
CrossRef77
Adriana Weinberg, Lin-Ye Song, Terence Fenton, Sharon A. Nachman, Jennifer S. Read, Julie Patterson-Bartlett, Myron J. Levin. (2010) T Cell Responses of HIV-Infected Children after Administration of Inactivated or Live Attenuated Influenza Vaccines. AIDS Research and Human Retroviruses 26:1, 51-59
CrossRef78
Dirk Bumann, Christoph Behre, Katharina Behre, Steffen Herz, Britta Gewecke, J. Engelbert Gessner, Bernd Ulrich von Specht, Ulrich Baumann. (2010) Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: A clinical trial of immunogenicity in lower airways of human volunteers. Vaccine 28:3, 707-713
CrossRef79
Leonard R. Krilov. (2009) Influenza Vaccines: The Key to Disease Prevention and Control. Pediatric Annals 38:12, 650-654
CrossRef80
Sebastian U. Schnitzler, Paul Schnitzler. (2009) An update on swine-origin influenza virus A/H1N1: a review. Virus Genes 39:3, 279-292
CrossRef81
Pierre J.T. De Villiers, A. Duncan Steele, Louis A. Hiemstra, Ruth Rappaport, Andrew J. Dunning, William C. Gruber, Bruce D. Forrest. (2009) Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 28:1, 228-234
CrossRef82
Stan L. Block. (2009) The Daunting Practicalities of In-Office Pediatric Influenza Vaccination: 2009–2010. Pediatric Annals 38:12, 655-660
CrossRef83
Laura L. Hammitt, Julie Patterson Bartlett, Shaobing Li, Jeremy Rahkola, Nancy Lang, Edward N. Janoff, Myron J. Levin, Adriana Weinberg. (2009) Kinetics of viral shedding and immune responses in adults following administration of cold-adapted influenza vaccine. Vaccine 27:52, 7359-7366
CrossRef84
John M Kelso. (2009) Update on vaccination guidelines for allergic children. Expert Review of Vaccines 8:11, 1541-1546
CrossRef85
Michele Michael, Elizabeth Helm, Brigit Van Graafeiland, Frank Malinoski, Jay Bauman. (2009) Influenza Vaccination with a Live Attenuated Vaccine. AJN, American Journal of Nursing 109:10, 44-48
CrossRef86
N. E. Basta, D. L. Chao, M. E. Halloran, L. Matrajt, I. M. Longini. (2009) Strategies for Pandemic and Seasonal Influenza Vaccination of Schoolchildren in the United States. American Journal of Epidemiology 170:6, 679-686
CrossRef87
Robert F. Breiman, W. Abdullah Brooks, Doli Goswami, Rosanna Lagos, Charissa Borja-Tabora, Claudio F. Lanata, Jaime A. Cèspedes Londoño, Lucy Chai See Lum, Ruth Rappaport, Ahmad Razmpour, Robert E. Walker, William C. Gruber, Bruce D. Forrest. (2009) A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. Vaccine 27:40, 5472-5479
CrossRef88
Arnold S. Monto, Filippo Ansaldi, Richard Aspinall, Janet E. McElhaney, Luis F. Montaño, Kristin L. Nichol, Joan Puig-Barberà, Joe Schmitt, Iain Stephenson. (2009) Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 27:37, 5043-5053
CrossRef89
Yoshikazu Yuki, Hiroshi Kiyono. (2009) Mucosal vaccines: novel advances in technology and delivery. Expert Review of Vaccines 8:8, 1083-1097
CrossRef90
Ruth A. Karron, Kawsar Talaat, Catherine Luke, Karen Callahan, Bhagvanji Thumar, Susan DiLorenzo, Josephine McAuliffe, Elizabeth Schappell, Amorsolo Suguitan, Kimberly Mills, Grace Chen, Elaine Lamirande, Kathleen Coelingh, Hong Jin, Brian R. Murphy, George Kemble, Kanta Subbarao. (2009) Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 27:36, 4953-4960
CrossRef91
Cynthia J. Mears, Elisa N. Lawler, Lee D. Sanders, Ben Z. Katz. (2009) Efficacy of LAIV-T on Absentee Rates in a School-Based Health Center Sample. Journal of Adolescent Health 45:1, 91-94
CrossRef92
Timo Vesikari, Michele Pellegrini, Aino Karvonen, Nicola Groth, Astrid Borkowski, Derek T. OʼHagan, Audino Podda. (2009) Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant. The Pediatric Infectious Disease Journal 28:7, 563-571
CrossRef93
Gabriele Neumann, Takeshi Noda, Yoshihiro Kawaoka. (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459:7249, 931-939
CrossRef94
Niels Hagenaars, Enrico Mastrobattista, Rolf J. Verheul, Imke Mooren, Harrie L. Glansbeek, Jacco G. M. Heldens, Han Bosch, Wim Jiskoot. (2009) Physicochemical and Immunological Characterization of N,N,N-Trimethyl Chitosan-Coated Whole Inactivated Influenza Virus Vaccine for Intranasal Administration. Pharmaceutical Research 26:6, 1353-1364
CrossRef95
Humberto Bracco Neto, Calil K. Farhat, Miguel Wenceslao Tregnaghi, Shabir A. Madhi, Ahmad Razmpour, Giuseppe Palladino, Margaret G. Small, William C. Gruber, Bruce D. Forrest. (2009) Efficacy and Safety of 1 and 2 Doses of Live Attenuated Influenza Vaccine in Vaccine-Naive Children. The Pediatric Infectious Disease Journal 28:5, 365-371
CrossRef96
Barbara Watts. (2009) Outpatient management of asthma in children age 5-11 years: Guidelines for practice. Journal of the American Academy of Nurse Practitioners 21:5, 261-269
CrossRef97
Carlos G. Grijalva, Yuwei Zhu, Marie R. Griffin. (2009) Evidence of effectiveness from a large county-wide school-based influenza immunization campaign. Vaccine 27:20, 2633-2636
CrossRef98
Arnold S Monto, Suzanne E Ohmit. (2009) Seasonal influenza vaccines: evolutions and future trends. Expert Review of Vaccines 8:4, 383-389
CrossRef99
De-chu C Tang, Jianfeng Zhang, Haroldo Toro, Zhongkai Shi, Kent R Van Kampen. (2009) Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines. Expert Review of Vaccines 8:4, 469-481
CrossRef100
David Liebowitz, Bin Lu. (2009) Making improvements in influenza vaccines: incremental change or transformational evolution?. Future Virology 4:2, 133-141
CrossRef101
Anna Bekker, Courtney Chou, Henry H Bernstein. (2009) Update on universal annual influenza immunization recommendations for children. Current Opinion in Pediatrics 21:1, 122-126
CrossRef102
Janelle Rhorer, Christopher S. Ambrose, Stephanie Dickinson, Holli Hamilton, Napoleon A. Oleka, Frank J. Malinoski, Janet Wittes. (2009) Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine 27:7, 1101-1110
CrossRef103
Jamie FS Mann, Reinaldo Acevedo, Judith del Campo, Oliver Pérez, Valerie A Ferro. (2009) Delivery systems: a vaccine strategy for overcoming mucosal tolerance?. Expert Review of Vaccines 8:1, 103-112
CrossRef104
Arnold S. Monto. (2009) The Risk of Seasonal and Pandemic Influenza: Prospects for Control. Clinical Infectious Diseases 48:S1, S20-S25
CrossRef105
Joel R. Haynes, Leslie Dokken, James A. Wiley, Andrew G. Cawthon, John Bigger, Allen G. Harmsen, Charles Richardson. (2009) Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 27:4, 530-541
CrossRef106
Michelle A. Gill, Kristin Long, Theresa Kwon, Luz Muniz, Asuncion Mejias, John Connolly, Lonnie Roy, Jacques Banchereau, Octavio Ramilo. (2008) Differential Recruitment of Dendritic Cells and Monocytes to Respiratory Mucosal Sites in Children with Influenza Virus or Respiratory Syncytial Virus Infection. The Journal of Infectious Diseases 198:11, 1667-1676
CrossRef107
Joseph E Kerschner. (2008) Bench and bedside advances in otitis media. Current Opinion in Otolaryngology & Head and Neck Surgery 16:6, 543-547
CrossRef108
Menachem Rottem. (2008) Asthma prevalence and exacerbations in children: is there an association with childhood vaccination?. Expert Review of Clinical Immunology 4:6, 687-694
CrossRef109
Bram Palache. (2008) New vaccine approaches for seasonal and pandemic influenza. Vaccine 26:49, 6232-6236
CrossRef110
Timo Vesikari. (2008) Emerging Data on the Safety and Efficacy of Influenza Vaccines in Children. The Pediatric Infectious Disease Journal 27:Supplement, S159-S161
CrossRef111
Christopher S. Ambrose, Catherine Luke, Kathleen Coelingh. (2008) Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza and Other Respiratory Viruses 2:6, 193-202
CrossRef112
Peter F. Wright, Edith Sannella, Jian R. Shi, Yuwei Zhu, Mine R. Ikizler, Kathryn M. Edwards. (2008) Antibody Responses After Inactivated Influenza Vaccine in Young Children. The Pediatric Infectious Disease Journal 27:11, 1004-1008
CrossRef113
Takeshi Ichinohe, Akiko Iwasaki, Hideki Hasegawa. (2008) Innate sensors of influenza virus: clues to developing better intranasal vaccines. Expert Review of Vaccines 7:9, 1435-1445
CrossRef114
Jun Kunisawa, Tomonori Nochi, Hiroshi Kiyono. (2008) Immunological commonalities and distinctions between airway and digestive immunity. Trends in Immunology 29:11, 505-513
CrossRef115
N. E. Basta, M. E. Halloran, L. Matrajt, I. M. Longini. (2008) Estimating Influenza Vaccine Efficacy From Challenge and Community-based Study Data. American Journal of Epidemiology 168:12, 1343-1352
CrossRef116
Mary Hoelscher, Shivaprakash Gangappa, Weimin Zhong, Lakshmi Jayashankar, Suryaprakash Sambhara. (2008) Vaccines against epidemic and pandemic influenza. Expert Opinion on Drug Delivery 5:10, 1139-1157
CrossRef117
Ulrich Baumann. (2008) Mucosal vaccination against bacterial respiratory infections. Expert Review of Vaccines 7:8, 1257-1276
CrossRef118
W Paul Glezen. (2008) Universal Influenza Vaccination and Live Attenuated Influenza Vaccination of Children. The Pediatric Infectious Disease Journal 27:Supplement, S104-S109
CrossRef119
Marc Girard, Laszlo Palkonyay, Marie Paule Kieny. (2008) Report of the 4th meeting on the “Evaluation of pandemic influenza prototype vaccines in clinical trials”. Vaccine 26:39, 4975-4977
CrossRef120
Robert B. Belshe, Christopher S. Ambrose, Tingting Yi. (2008) Safety and efficacy of live attenuated influenza vaccine in children 2–7 years of age. Vaccine 26, D10-D16
CrossRef121
Robert B. Couch. (2008) Seasonal inactivated influenza virus vaccines. Vaccine 26, D5-D9
CrossRef122
Tatiana Chirkova, Galina Petukhova, Daniil Korenkov, Anatoliy Naikhin, Larisa Rudenko. (2008) Immunization with live influenza viruses in an experimental model of allergic bronchial asthma: infection and vaccination. Influenza and Other Respiratory Viruses 2:5, 165-174
CrossRef123
Stan L. Block, Ram Yogev, Frederick G. Hayden, Christopher S. Ambrose, Wen Zeng, Robert E. Walker. (2008) Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5–49 years of age. Vaccine 26:38, 4940-4946
CrossRef124
Kristin L. Nichol. (2008) Efficacy and effectiveness of influenza vaccination. Vaccine 26, D17-D22
CrossRef125
Myron J. Levin, Lin-Ye Song, Terrence Fenton, Sharon Nachman, Julie Patterson, Robert Walker, George Kemble, Maria Allende, Micki Hultquist, Tingting Yi, Barbara Nowak, Adriana Weinberg. (2008) Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 26:33, 4210-4217
CrossRef126
William Paul Glezen. (2008) Modifying Clinical Practices to Manage Influenza in Children Effectively. The Pediatric Infectious Disease Journal 27:8, 738-743
CrossRef127
Suzanne E. Ohmit, John C. Victor, Esther R. Teich, Rachel K. Truscon, Judy R. Rotthoff, Duane W. Newton, Sarah A. Campbell, Matthew L. Boulton, Arnold S. Monto. (2008) Prevention of Symptomatic Seasonal Influenza in 2005–2006 by Inactivated and Live Attenuated Vaccines. The Journal of Infectious Diseases 198:3, 312-317
CrossRef128
Jean Hamlin, Selvi Senthilnathan, Henry H Bernstein. (2008) Update on universal childhood immunizations. Current Opinion in Pediatrics 20:4, 483-489
CrossRef129
Catherine WM Ong, Paul Ananth Tambyah. (2008) Update on antivirals and vaccines for seasonal and potential pandemic use. Expert Review of Respiratory Medicine 2:3, 391-402
CrossRef130
Bryan R. Luce, Kristin L. Nichol, Robert B. Belshe, Kevin D. Frick, Su Xia Li, Audra Boscoe, Matthew D. Rousculp, Parthiv J. Mahadevia. (2008) Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States. Vaccine 26:23, 2841-2848
CrossRef131
Marc P. Girard, Albert Osterhaus, Yuri Pervikov, Laszlo Palkonyay, Marie Paule Kieny. (2008) Report of the third meeting on “Influenza vaccines that induce broad spectrum and long-lasting immune responses”, World Health Organization, Geneva, Switzerland, 3–4 December 2007. Vaccine 26:20, 2443-2450
CrossRef132
Antoine Minne, François Huaux, Joanna Jaworska, Ro-Dug Rha, Eckard Hamelmann, Rita Vanbever. (2008) Safety evaluation of pulmonary influenza vaccination in healthy and “asthmatic” mice. Vaccine 26:19, 2360-2368
CrossRef133
Natasa Strbo, Eckhard R. Podack. (2008) REVIEW ARTICLE: Secreted Heat Shock Protein gp96-Ig: An Innovative Vaccine Approach. American Journal of Reproductive Immunology 59:5, 407-416
CrossRef134
Manjusha J. Gaglani, Pedro A. Piedra, Mark Riggs, Gayla Herschler, Charles Fewlass, W Paul Glezen. (2008) Safety of the Intranasal, Trivalent, Live Attenuated Influenza Vaccine (LAIV) in Children With Intermittent Wheezing in an Open-Label Field Trial. The Pediatric Infectious Disease Journal 27:5, 444-452
CrossRef135
Christopher J Cates, Tom Jefferson, Brian H Rowe, Christopher J Cates. 2008. Vaccines for preventing influenza in people with asthma. .
CrossRef136
Shetal I. Shah, Martha Caprio. (2008) Availability of Trivalent Inactivated Influenza Vaccine to Parents of Neonatal Intensive Care Unit Patients and Its Effect on the Healthcare Worker Vaccination Rate. Infection Control and Hospital Epidemiology 29:4, 309-313
CrossRef137
Xiao‐Song He, Tyson H. Holmes, Kutubuddin Mahmood, George W. Kemble, Cornelia L. Dekker, Ann M. Arvin, Harry B. Greenberg. (2008) Phenotypic Changes in Influenza‐Specific CD8 + T Cells after Immunization of Children and Adults with Influenza Vaccines. The Journal of Infectious Diseases 197:6, 803-811
CrossRef138
Paul A. TAMBYAH. (2008) Update on influenza vaccines. Respirology 13:s1, S41-S43
CrossRef139
Stephen B. Lambert, Kelly M. Allen, Terence M. Nolan. (2008) Parent-collected respiratory specimens—A novel method for respiratory virus and vaccine efficacy research. Vaccine 26:15, 1826-1831
CrossRef140
Thierry van den Berg, Bénédicte Lambrecht, Sylvie Marché, Mieke Steensels, Steven Van Borm, Michel Bublot. (2008) Influenza vaccines and vaccination strategies in birds. Comparative Immunology, Microbiology and Infectious Diseases 31:2-3, 121-165
CrossRef141
John Iskander, Karen Broder. (2008) Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience. Expert Review of Vaccines 7:1, 75-82
CrossRef142
Petr O. Ilyinskii, Galini Thoidis, Alexander M. Shneider. (2008) Development of a Vaccine Against Pandemic Influenza Viruses: Current Status and Perspectives. International Reviews of Immunology 27:6, 392-426
CrossRef143
&NA;. (2008) Influenza Vaccine 2007–2008. Obstetrics & Gynecology 111:1, 206-207
CrossRef144
Pritish K. Tosh, Thomas G. Boyce, Gregory A. Poland. (2008) Flu Myths: Dispelling the Myths Associated With Live Attenuated Influenza Vaccine. Mayo Clinic Proceedings 83:1, 77-84
CrossRef145
Rino Rappuoli. (2007) Bridging the knowledge gaps in vaccine design. Nature Biotechnology 25:12, 1361-1366
CrossRef146
R B Belshe. (2007) Translational Research on Vaccines: Influenza as an Example. Clinical Pharmacology & Therapeutics 82:6, 745-749
CrossRef147
H. Jin, S. Manetz, J. Leininger, C. Luke, K. Subbarao, B. Murphy, G. Kemble, K.L. Coelingh. (2007) Toxicological evaluation of live attenuated, cold-adapted H5N1 vaccines in ferrets. Vaccine 25:52, 8664-8672
CrossRef148
Clare L. Hibbert, Pedro A. Piedra, Kimmie K. McLaurin, Timo Vesikari, Josephine Mauskopf, Parthiv J. Mahadevia. (2007) Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine 25:47, 8010-8020
CrossRef149
Stephen I. Pelton. (2007) Prospects for Prevention of Otitis Media. The Pediatric Infectious Disease Journal 26:Supplement, S20-S22
CrossRef150
Richard J Whitley. (2007) The role of oseltamivir in the treatment and prevention of influenza in children. Expert Opinion on Drug Metabolism & Toxicology 3:5, 755-767
CrossRef151
Gideon Kersten, Hoang Hirschberg. (2007) Needle-free vaccine delivery. Expert Opinion on Drug Delivery 4:5, 459-474
CrossRef152
Jindrich Cinatl jr, Martin Michaelis, Hans W. Doerr. (2007) The threat of avian influenza A (H5N1). Part IV: development of vaccines. Medical Microbiology and Immunology 196:4, 213-225
CrossRef153
Sean R Bennett, Beth Brennan, Henry H Bernstein. (2007) Immunizations, neonatal hyperbilirubinemia and animal-induced injuries. Current Opinion in Pediatrics 19:4, 492-502
CrossRef154
P. L. B. Bruijnzeel. (2007) Vergelijking van de werkzaamheid van vaccinatie van kinderen met levend verzwakt influenzavirus en geïnactiveerd (dood) influenzavirus. MFM 45:8, 234-235
CrossRef155
John S. Tam, Maria Rosario Z. Capeding, Lucy Chai See Lum, Tawee Chotpitayasunondh, Zaifang Jiang, Li-Min Huang, Bee Wah Lee, Yuan Qian, Rudiwilai Samakoses, Somsak Lolekha, K Pillai Rajamohanan, S Noel Narayanan, Chellam Kirubakaran, Ruth Rappaport, Ahmad Razmpour, William C. Gruber, Bruce D. Forrest. (2007) Efficacy and Safety of a Live Attenuated, Cold-Adapted Influenza Vaccine, Trivalent Against Culture-Confirmed Influenza in Young Children in Asia. The Pediatric Infectious Disease Journal 26:7, 619-628
CrossRef156
Jacyntha A. Sterling. (2007) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 42:5, 481-486
CrossRef157
Cox, Nancy J., Bridges, Carolyn Buxton, . (2007) Inactivated and Live Attenuated Influenza Vaccines in Young Children — How Do They Compare?. New England Journal of Medicine 356:7, 729-731
Full Text
